4.6 Article

Tumor-Penetrating iRGD Peptide Inhibits Metastasis

Journal

MOLECULAR CANCER THERAPEUTICS
Volume 14, Issue 1, Pages 120-128

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-14-0366

Keywords

-

Categories

Funding

  1. National Cancer Institute of NIH [R01CA167174, R01CA152327]
  2. American Association of Cancer Research/Pancreatic Cancer Action Network
  3. San Diego Foundation
  4. NIH [CA121949]
  5. Susan Komen for Cure Foundation [KG110704]
  6. European Research Council
  7. Wellcome Trust [WT095077MA]
  8. NATIONAL CANCER INSTITUTE [R01CA167174, P30CA030199, R01CA152327, T32CA121949] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Tumor-specific tissue-penetrating peptides deliver drugs into extravascular tumor tissue by increasing tumor vascular permeability through interaction with neuropilin (NRP). Here, we report that a prototypic tumor-penetrating peptide iRGD (amino acid sequence: CRGDKGPDC) potently inhibits spontaneous metastasis in mice. The antimetastatic effect was mediated by the NRP-binding RXXK peptide motif (CendR motif), and not by the integrin-binding RGD motif. iRGD inhibited migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. The peptide induced dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects were prominently displayed when the cells were seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins. The antimetastatic activity of iRGD may provide a significant additional benefit when this peptide is used for drug delivery to tumors. (C) 2014 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available